See How Hire2Retire Can Drive Success for Your Organization |17th Jan 2025|

CASE STUDY

Hire2Retire Automates Resource Provisioning Helping Prometheus Biosciences in its Fight Against IBD

Superior "First Day at Work"
Data Security
Timely Terminations
Role based access control

Industry

Company Size

51-200 Employees

Implemented Solution

Customer

Situation

Considering unhealthy eating patterns or may be genetic disorders, as per a report by EFFCA, more than 10 million people around the globe are suffering from inflammatory bowel disease or IBD. While there is no permanent cure for this disease, if not diagnosed at the right time, the patient can suffer from severe abdominal pain, fatigue, or even has his Gastrointestinal (GI) tract permanently damaged. Unfortunately, most IBD patients get mistreated because of prevalent generalized and primitive treatment methods, which hardly make any difference to a patient’s health.

An innovative biotechnology company, Prometheus Biosciences, with its ground-breaking approach, promises to help patients in their fight against chronic IBD diseases like Crohn’s disease and ulcerative colitis. In an effort to provide a more precise diagnosis and accurate testing for IBD, researchers at Prometheus Biosciences have spent more than two decades combining patient data with drug development insights, creating a novel precision therapy approach.

Struggles and Pains

It all started more than twenty years ago when Dr. Stephan Targan, in a medical center near Los Angeles, discovered transmembrane protein TL1A by pairing longitudinal clinical information with IBD patient bio-samples. With this innovation, he created an IBD Biobank and laid the foundation of Precision IBD. Over the years, this IBD Biobank evolved with the biotech and industry expertise of the members. In 2016, under the guidance of Scott Glenn and Jim Laur, the company was renamed Prometheus Biosciences.

Having spent years developing, testing, and validating their research and recently launching their IPO in March 2021, ensuring data and cyber security naturally becomes a high priority for the company. The operations of its development and research team might be way ahead of time, but the HR and business operations of the company were not very efficient because of manual interventions. The company faced various challenges in implementing access regulations and giving satisfactory experience to its new hires while maintaining compliance requirements.

In order to protect its valuable research data, Prometheus Biosciences needed a solution that ensures only trusted employees had access to high-level data and its terminated staff did not walk away with critical information. With these challenges in mind, they reached out to RoboMQ.

Resolution

RoboMQ, by implementing its flagship product Hire2Retire as a pre-packaged endto-end integration product, helped Prometheus Biosciences safeguard its research and sensitive data collected over the years. Hire2Retire integrated the companys HRIS ADP with Hybrid AD(Active Directory), creating a stringent role-based access control system that regulates resource allocation and eliminates security and compliance risks. Through end-to-end automation in employee lifecycle management and identity provisioning, Prometheus Biosciences could

Synchronize employee profile data from ADP to AD in real-time.

Easily and efficiently create and update security groups.

Maintain compliance with privacy and security regulations, eliminating the need for manual updates.

Ensure data security by removing the access of terminated employees in near real-time.

Want to learn more?

Ready to join the wave of companies automating their employee lifecycle management processes with Hire2Retire? Schedule a demo call with us today to see what Hire2Retire can do for your business.

RoboMQ is not affiliated, associated, authorized, endorsed by, or in any way officially connected with any of HR systems that it provides integration with and are mentioned in this case study. All product and company names are the registered trademarks of their original owners. 

MORE CASE STUDIES